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ABSTRACT
Osteopontin (OPN) is a secreted glycoprotein, that belongs to the non-structural 
extracellular matrix (ECM), and its over expression in human prostate cancer has been 
associated with disease progression, androgen independence and metastatic ability. 
Nevertheless, the pathophysiology of OPN in prostate tumorigenesis has never been 
studied. We crossed TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) 
mice with OPN deficient (OPN−/−) mice and followed tumor onset and progression 
in these double mutants. Ultrasound examination detected the early onset of a 
rapidly growing, homogeneous and spherical tumor in about 60% of OPN−/− TRAMP 
mice. Such neoplasms seldom occurred in parental TRAMP mice otherwise prone 
to adenocarcinomas and were characterized for being androgen receptor negative, 
highly proliferative and endowed with neuroendocrine (NE) features. Gene expression 
profiling showed up-regulation of genes involved in tumor progression, cell cycle and 
neuronal differentiation in OPN-deficient versus wild type TRAMP tumors. Down-
regulated genes included key genes of TGFa pathway, including SMAD3 and Filamin, 
which were confirmed at the protein level. Furthermore, NE genes and particularly 
those characterizing early prostatic lesions of OPN-deficient mice were found to 
correlate with those of human prostate NE tumours. These data underscore a novel 
role of OPN in the early stages of prostate cancer growth, protecting against the 
development of aggressive NE tumors.
INTRODUCTION
Prostate carcinoma (PCa) is one of the most 
common tumors in developed countries and the second 
leading cause of cancer-related death in the USA [1]. PCa 
is a multifocal disease, which progresses from high-grade 
prostate intraepithelial neoplasia (PIN). Initially, the tumor 
responds to therapies that mainly consist in androgen 
ablation, but it eventually becomes androgen resistant due 
to alterations in androgen receptor expression or related 
signalling. The main drivers of PCa development and 
progression are still unknown and effective therapies for 
the androgen-resistant stage are not yet available.
Stromal microenvironment modifications occurring 
at the stage of precancerous PIN lesions are no longer 
considered bystanders. In this context, SIBLINGs (Small 
Integrin-Binding Ligand N-Linked Glycoproteins), a 
family of non-structural extracellular matrix (ECM) 
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proteins, seem to favor tumor progression by hijacking 
their physiological functions in wound healing and tissue 
remodeling [2].
Osteopontin (OPN) is a secreted protein, belonging 
to SIBLINGs, present in body fluids and almost ubiquitous 
in tissues. OPN contributes to tissue homeostasis through 
the regulation of stem cell pools within specific niches [3]. 
OPN over-expression in human PCa has been associated 
with disease progression towards androgen independence 
and metastasis [4, 5]. Therefore, at the late stages of PCa 
OPN targeted inactivation might be a promising strategy. 
However, the role of OPN at onset of PCa has not been 
investigated so far. To address this issue, we crossed 
OPN deficient (OPN−/−) mice with the TRansgenic 
Adenocarcinoma of the Mouse Prostate (TRAMP) mice, 
which carry the SV40 large T antigen (Tag) under the 
control of the rat probasin regulatory element, selectively 
activated by androgens in the prostate epithelia. TRAMP 
mice invariantly develop PIN (8-16 weeks) that progresses 
to focal invasive adenocarcinoma (16-20 weeks) and 
then to moderately differentiated (24 weeks) and poorly 
differentiated (24-30 weeks) adenocarcinoma [6, 7].
Although the reported over-expression of OPN 
in advanced disease let envisage tumor reduction in 
OPN−/−TRAMP mice, we unexpectedly observed the 
early onset of highly proliferative, anaplastic androgen-
independent tumors, characterized by a neuroendocrine 
(NE) phenotype. The corresponding human NE carcinoma 
characterized by aggressive behaviour, poor response to 
standard treatments and dismal prognosis [8, 9] accounts 
for nearly 10% of cases and seldom occurs in relatively 
young patients. Notably, areas of NE differentiation 
occur in advanced PCa patients after androgen ablation 
therapy [10, 11]. Five to ten percent of TRAMP mice 
spontaneously develop tumors with the NE phenotype. 
The mechanisms driving their onset in OPN deficiency 
are here investigated [12].
RESULTS
OPN deletion enhances anaplastic tumor 
development in TRAMP mice
We followed tumor onset and progression in 
OPN−/−TRAMP (n = 14) and TRAMP (n = 16) mice 
between 12 and 30 weeks (wks) of age by ultrasound 
(US) echographic examination. US allows evaluating 
prostate morphology and dimensions, and the elastomeric 
response to the echographic probe pressure, highlighting 
density alterations. The scan performed in 3D mode 
allows inspection of every prostatic lobe for the presence 
of tumor before it becomes palpable. US and histologic 
analyses of the prostate revealed no differences between 
the two strains until mice were 15 wks old. Between 18 
and 22 wks of age a large, well-defined spheroid tumor 
appeared in OPN−/−TRAMP (Figure 1A and 1B) but not in 
age-matched TRAMP mice (Figure 1A). These spheroid 
tumors were even larger than the heterogeneous and 
multifocal tumors, also infiltrating the seminal vesicles, 
that characterize 30 wks old TRAMP mice (Figure 1A). 
Such growth differences were confirmed by weighting the 
genitourinary organs after necropsy at 30 wks of age or 
following mice survival (Figure 1C).
Histopathological analysis was performed on 
cohorts of mice sacrificed at different time points (18 to 20 
wks, 20 to 30 wks, > 30 wks). Anaplastic lesions (Figure 
1D, right) were present in roughly 60% of OPN−/−TRAMP 
mice in all cohorts, but only in few TRAMP mice and 
only after the 20th week of age (Table 1). Conversely, 
multifocal adenocarcinoma lesions (Figure 1D, left) were 
present in the majority of TRAMP mice at all time points 
(Table 1). As expected, positivity for OPN was found 
in both epithelial and stromal cells in TRAMP prostates 
(Figure 1E).
To compare the anaplastic lesions from the two 
strains, tumors were collected at 30 wks of age for 
histopathology and immunohistochemistry. At this 
age, both strains develop poorly differentiated lesions. 
However, tumors formed in OPN−/−TRAMP mice were 
characterized by marked anaplasia and higher expression 
of Ki67, N-cadherin and laminin (Figure 2).
These data suggest that the lack of OPN at the 
beginning of the transformation process skews the 
nascent tumor towards a more aggressive, undifferentiated 
phenotype.
Absence of OPN promotes androgen-
independent tumor growth in the early stages 
of prostate carcinogenesis
Androgen receptor was expressed by normal and 
transformed glandular prostatic tissue of TRAMP mice 
(Figure 3A) as well as by normal epithelial cells of 
OPN−/− TRAMP prostates, but not by tumors of OPN−/− 
TRAMP mice (Figure 3B). This finding suggested that 
in OPN−/−TRAMP mice tumors could rise as androgen 
independent.
Androgen ablation is a standard treatment for 
patients with advanced PCa (www.cancer.gov/types/
prostate/hp/prostate-treatment-pdq#section/all). 
Unfortunately these patients frequently develop androgen 
resistance and ineffective treatment options remain. This 
setting can be modeled in TRAMP mice by castration [13]. 
We investigated whether the lack of OPN affects mice 
susceptibility to hormone withdrawal in early phases of 
tumor development. TRAMP and OPN−/−TRAMP mice 
(both n = 11) were castrated before sexual maturation 
(6 wks) and tumor growth was monitored by US 
examination. Among castrated TRAMP mice, 9 showed 
prostate involution, 1 developed adenocarcinoma and the 
remaining one developed an anaplastic spheroid tumor 
with incidence similar to that of non-castrated TRAMP 
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mice (12%; Figure 3C). Castrated OPN−/−TRAMP mice 
did not develop any evident adenocarcinoma, whereas 
8 showed anaplastic tumors (73%, versus 60% of non-
castrated littermates). Prostate involution occurred in the 
remaining 3 (27%) castrated mice (Figure 3C). Castration 
after sexual maturation (12 wks) did not change the 
Figure 1: OPN-/- TRAMP mice develop anaplastic tumors with increased frequency. A. TRAMP and OPN-/- TRAMP 
mice (n = 16 and 14, respectively) were followed for tumor growth by echographic ultrasound examination. Representative echographic 
abdominal imaging of prostate of 18wks (left) and 30wks old TRAMP (center) or 18 wks old OPN−/−TRAMP (right) mice are reported. Red 
dashed lines outline tumor mass. Scale bars at the borders are in millimeters. B. 3D rendering of echographic images of prostatic tumor 
growth (outlined in red) in a OPN−/−TRAMP mouse at 16, 20, 22 wks. C. Left: Mice followed echographically as described in (a) were 
euthanized at 30 wks of age. Graph reports weight of genitourinary apparatus of TRAMP (n = 16) and OPN−/−TRAMP (n = 14) as indicator 
of tumor burden (Student’s T test: ***: p < 0.0001). Right: Alternatively, two other cohorts of TRAMP (n = 26) and OPN−/− TRAMP (n 
= 15) mice were followed for survival; graph depicts Kaplan-Meier survival curve (Log Rank test: ***: p < 0.0001). D. Representative 
H&E staining of adenocarcinoma developing in 30 wks old TRAMP mice or anaplastic tumors grown in 18 wks old OPN−/−TRAMP mice. 
Magnification x200. At least 3 mice per group/age were analyzed and one representative picture is reported. E. Representative OPN staining 
in adenocarcinoma samples developing in 30 wks old TRAMP mice. Magnification x400. Arrows highlight positive cells. At least 3 mice 
per group/age were analyzed and one representative picture is reported.
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Table 1: Percentage of mutifocal or anaplastic lesions detected by histology in prostates of 
TRAMP or OPN-/- TRAMP mice at the indicated time points
18<wks<20 (n = 7 TRAMP; 
n = 7 OPN-/-TRAMP)
20<wks<30 (n = 15 TRAMP; 
n = 15 OPN-/-TRAMP)














TRAMP 100% 0% 78% 22% 93% 7%
OPN -/- 
TRAMP 50% 50% 40% 60% 46% 54%
Figure 2: Phenotype of anaplastic lesions developing in TRAMP and OPN-/-TRAMP mice. Representative hematoxilin 
and eosin (H&E) staining and immunohistochemistry for Ki67, N-cadherin and Laminin of anaplastic tumors developing in 30 wks old 
TRAMP and OPN−/−TRAMP mice as indicated. Magnification ×400. At least 3 mice per group were analyzed and one representative picture 
is reported.
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Figure 3: Anaplastic tumors developing in OPN-/- TRAMP mice are androgen independent and express NE markers. 
A–B. Representative immunohistochemistry staining of androgen receptor (AR) showing positivity in transformed prostates of 18 wks 
TRAMP mice (A), and in healthy glands surrounding tumor mass in age-matched OPN−/−TRAMP mice (B). Tumor areas in OPN−/− TRAMP 
mice were AR negative (B). Magnification x400. At least 3 mice per group were analyzed and one representative picture is reported. 
C. Frequency of prostatic lesions in TRAMP and OPN−/−TRAMP either intact, or castrated at 6 (n = 11 for both groups) or 12 wks (n = 4 
and 7, respectively) and sacrificed at 30 wks of age. (Fisher exact test *: p < 0.05; **: p < 0.01; ****: p < 0.0001) D–F. Representative Tag 
staining in prostate of intact TRAMP mice (D), in regressed prostate (E) or in anaplastic tumors (F) emerged in TRAMP mice after being 
castrated at 12 wks. Magnification x 200. G–I. Representative Tag staining in anaplastic prostate tumors developed in OPN−/−TRAMP 
mice either intact (G), castrated at 6 wks (H), or at 12 wks (I). L–N. Representative synaptophisin (Syp) staining in tumors developed in 
OPN−/−TRAMP mice either intact (L) or castrated at 6 wks (M) or in OPN−/−TRAMP mice showing prostate involution after castration (N). 
Arrows indicate positive cells. Magnification x 200.
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incidence of anaplastic tumors in OPN−/−TRAMP mice, 
but increased up to 25% the rate of anaplastic tumors in 
TRAMP mice (Figure 3C) as expected [13, 14].
In TRAMP mice the expression of Tag is controlled 
by the rat Probasin promoter [6] which is regulated 
by androgens [15]. That means that Tag expression 
in TRAMP mice reflects androgen responsiveness of 
epithelial prostate cells. Immunohistochemistry revealed 
Tag expression by luminal cells of intact tumorigenic 
prostate glands of TRAMP mice (Figure 3D) but not by 
cells of involute prostates (Figure 3D). As already seen 
by others [13, 16], Tag expression was maintained in cells 
of anaplastic lesions occurring in castrated TRAMP mice 
(Figure 3F). Interestingly, Tag was expressed at high levels 
on anaplastic tumors of OPN−/−TRAMP mice regardless 
castration (Figure 3G–3I). These results confirmed that 
the anaplastic tumors arising in OPN−/−TRAMP mice 
developed as androgen-independent.
Synaptophysin staining confirmed the NE phenotype 
of anaplastic tumors [12] developed in both non-castrated 
(Figure 3L) and castrated (Figure 3M) OPN−/−TRAMP 
mice. Synaptophysin did not stain the epithelia of 
OPN−/−TRAMP prostates regressed because of castration 
(Figure 3N). Therefore, thereafter in this manuscript 
tumors from OPN−/− TRAMP mice will be referred as NE 
tumors.
To test the possible OPN source either epithelial 
or hematopoietic that is relevant in this experimental 
model, bone marrow (BM) transplantation was 
performed to obtain chimeras lacking or not OPN in 
the prostatic epithelium or in the radio-resistant stroma 
cell components. In detail, BM from OPN-competent 
wild-type (WT) mice was transplanted into 6 wks old 
OPN−/−TRAMP mice as well as BM, either from OPN−/− 
or WT mice, was transplanted into TRAMP mice. Mice 
were then sacrificed at 30 wks of age for histopathologic 
analysis of prostates. NE tumor frequency remained 
determined by the host genotype regardless that of donor 
BM, with high incidence in OPN−/−TRAMP and low 
incidence in TRAMP recipient chimeras (Figure S1). 
These results suggest that OPN produced by the host 
radio-resistant cell component contrast the occurrence of 
NE tumors.
Basal origin of tumors in OPN−/−TRAMP mice
Whether prostatic NE cancers have a distinct cellular 
origin from adenocarcinomas or rather they originate from 
the peculiar differentiation of common precursors is still 
debated. As far as the TRAMP model is concerned, it is 
believed that NE tumors can arise from a subset of stem/
progenitor cells populating the basal cell layer of glandular 
ducts [12, 17, 18]. We thus tested the expression of the 
basal p63, [19–21] and the luminal CK8 [22] markers in 
association with the cell proliferation marker Ki67.
In prostate lobes of 15 wks old TRAMP mice, 
clusters of proliferating cells co-expressed Ki67 and 
CK8 (Figure 4A) whereas p63 positive cells were Ki67 
negative (Figure 4C). On the contrary, in prostates of 
OPN−/−TRAMP mice luminal CK8 cells mostly lacked 
Ki-67 (Figure 4B), which instead co-localized with p63 
in the basal compartment (Figure 4D). Notably, according 
to previous reports on prostate cancer patients [21], some 
cytoplasmic staining of p63 was detectable (Figure 4C 
and 4D) whereas nuclear p63 localization was canonic in 
normal prostate of wild-type mice (Figure S2).
Gene expression profile confirms the NE 
phenotype of OPN−/−TRAMP tumors
To obtain a broad view of the transcriptional 
features distinctive of NE and adenocarcinoma lesions, 
we compared gene expression profiles of prostate 
samples collected from 18 weeks old OPN−/−TRAMP 
mice bearing macroscopic NE lesions (OPT-tm) with 
those from 30 wks old TRAMP mice (T30) representative 
of adenocarcinomas (ADC). A detailed description of 
samples used from microarray comparison is reported in 
Suppl. Table 1, and a detailed flow of samples comparison 
is shown in Suppl. Figure 3
Unsupervised hierarchical clustering clearly 
distinguished gene expression profiles of TRAMP mice 
with adenocarcinoma from OPN−/−TRAMP mice with 
NE tumor (Figure S4). We found 2536 differentially 
expressed genes between the two classes (absolute fold 
change ≥ 2 and FDR < 5%; Heatmap in Figure 5A). 
To identify biological processes distinguishing the two 
histotypes we performed Gene Set Enrichment Analysis 
(GSEA) using gene sets compiled from canonical 
pathway and Gene Ontology databases. Significant gene 
sets (FDR < 5%, p-value < 0.001) were visualized as 
interaction networks using the Enrichment map plugin 
in Cytoscape (Figure S5). NE tumors were characterized 
by the activation of gene sets involved in cell cycle 
and proliferation, transcription and RNA-processing, 
and neural system. These findings were confirmed by 
functional analysis of the differentially expressed genes 
using Ingenuity Pathway Analysis (IPA) software. In 
OPT-tm, among genes involved in cell cycle, E2f2 and 
Ccne2 were the most up-regulated, while Ccnd1, whose 
up-regulation has been reported in TRAMP mice [23, 
24], was the most down-regulated. These results were 
confirmed by RT-qPCR analysis (Figure 5B) and were 
concordant with the high cellular proliferative rate 
observed both macroscopically and histologically in 
OPN−/−TRAMP tumors. The most up-regulated genes 
in OPT-tm samples were those involved in neurological 
diseases and in neuronal system development, including 
L-Dopa Decarboxylase (Ddc, fold change = 172.2) and 
synaptophisin (Syp, fold change = 31.3), confirming 
Oncotarget3911www.impactjournals.com/oncotarget
the NE phenotype of anaplastic tumors arising in 
OPN−/−TRAMP mice. Upregulation at protein level of 
DDC and SYP in NE tumors was validated by western 
blot (Figure 5C).
IPA predicted Tgfb1 to be an uprstream regulator 
of the differentially expressed genes in OPT-tm samples 
(p = 8.93e-37). Indeed 157 targets of Tgfb1 were listed 
as differentially expressed genes and 84 of them had an 
expression consistent with Tgfb1 pathway inhibition. 
This finding was supported by the significant down-
regulation of Tgfb1 in OPT-tm (FDR=0.005), although 
this gene was excluded from the list of differentially 
expressed genes because of a fold-change of -1.53. 
Moreover, Filamin A (FLNA), a key TGFβ activator 
[25], was among the down-regulated genes in our 
signature and western blot confirmed FLNA protein 
down regulation (Figure 5C).
Tgfbr2 and Tgfbr3 transcripts were significantly 
down-regulated in OPT-tm, whereas Tgfbr1, which is 
responsible for SMADs phosphorylation and activation, 
was up-regulated. As protein levels of TGFbRI and TGFbRII 
were comparable between OPN−/−TRAMP NE tumors 
and TRAMP adenocarcinoma (not shown), we focused 
on proteins downstream the TGFβ pathway, particularly 
Smad2 and Smad3, which are crucial mediators of TGFβ 
activity in PCa [26]. Smad3 was down-regulated in GEP 
and in western blot in NE tumors from OPN−/−TRAMP mice 
(Figure 5D). On the contrary, Smad2 transcript and protein, 
as well as phosphorylation of SMAD3 and SMAD, remained 
unchanged in OPN−/−TRAMP NE tumors versus TRAMP 
adenocarcinomas (Figure 5D). These results suggested that 
in absence of OPN the TGFβ pathway and the cell cycle 
were down-regulated, likely through the activity of FLNA 
and SMAD3.
Figure 4: NE tumors of OPN-/-TRAMP mice have a basal phenotype. A–D. Representative immunofluorescence staining of 
Ki67 (green) and CK8 (red; panels A and B) and of Ki67 (green) and p63 (red; panels C and D) in prostates of TRAMP and OPN−/−TRAMP 
mice of 15 wks of age. Blue: dapi. White arrows indicate cells co-expressing Ki67 and CK8, while yellow arrows indicate cells 
co-expressing Ki67 and p63. Three mice per group were analyzed and one representative picture is reported.
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Figure 5: Gene expression profile confirms NE phenotype of OPN-/-TRAMP tumors. A. Heatmap of differentially expressed 
genes in NE tumors of 18 wks old OPN−/−TRAMP (OPT18_tm) vs adenocarcinoma (ADC) of 30 wks old TRAMP (T30) mice. Red and 
green color indicates relative expression as indicated. Refer to Suppl. Table 1 and Suppl. Figure3 for detailed description of samples 
analyzed and flow chart of comparisons. B. Relative expression +/- SD of E2f2, Ccne2 and Ccnd1 in prostates of 30 wks TRAMP and 18 
wks OPN-/-TRAMP mice as assessed by real-time PCR. Experiment was repeated twice with samples from three different mice per group. 
C. Western blot analysis for L-Dopa Decarboxylhase (DDC), synaptophysin (SYP) and Filamin (FLNA) in prostates of 30 wks TRAMP 
and 18 wks OPN-/-TRAMP mice. Values are quantified to internal control (GAPDH). Picture reports cropped blots around the specific 
bands. Experiment was repeated twice with samples from two different mice per group. D. Western blot analysis for SMAD2, SMAD3 
and their phosphorylated forms (pSMAD2 and pSMAD3, respectively) or β-actin (as control) in prostates of 30 wks TRAMP and 18 wks 
OPN-/-TRAMP mice. HeLa cells stimulated with TGFb were used as positive control (+). Values are quantified to internal control (β-actin). 
Picture reports cropped blots around the specific bands Experiment was repeated twice with samples from three different mice per group. 
Student’s T test: *: p < 0.0001.
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NE signature from early lesions of OPN−/− 
TRAMP mice is enriched in genes overexpressed 
in human NE prostate and can predict NE tumor 
outcome
We have the idea to test the possibility of defining a 
gene signature that could predict the onset of NE disease 
in PCa patients. Using the 2536 genes distinguishing 
NE from adenocarcinoma prostate tumors, we applied 
unsupervised hierarchical clustering to gene expression 
data from prostates of TRAMP mice of 18 wks of 
age (T18, n = 4) and from OPN−/− TRAMP mice of 15 
(n = 5) or 18 (n = 9) wks of age (OPT15 and OPT18, 
respectively) all devoid of US-detectable lesions (Table S1 
and Figure S3 describe samples and class comparisons). 
We found that early prostate samples fell into two distinct 
clusters (Figure 6a). The first cluster was composed 
of 5 samples, hereafter called Early-NE, whose gene 
expression pattern resembled that of NE OPT-tm. These 
samples were all from OPN−/−TRAMP mice (4 of 18 
wks old and 1 of 15 wks), indicating that at the time of 
sacrifice they were likely bearing a developing NE tumor, 
well before any possible diagnosis. The second cluster 
contained 17 samples, hereafter called Early-ADC, whose 
gene expression profile was similar to that of TRAMP 
adenocarcinomas. All early samples from TRAMP (T18) 
and from OPN−/− TRAMP mice, without NE features, fell 
into this cluster. To identify early markers specific for 
NE tumor a comparison between Early-NE and Early-
ADC GEPs was performed. We found that all the 184 
differentially expressed genes (absolute fold change ≥ 2 
and FDR < 5%), were upregulated in the Early-NE group 
(Figure 6A). According to GSEA these genes are involved 
in cell cycle and nervous system development, but also 
in down-regulation of pro-inflammatory processes (Figure 
6B, Table S2 and S3). This list of 184 genes provides a 
transcriptional profile distinguishing NE tumors from 
adenocarcinoma at early stages of transformation.
We were interested in asking whether the 
transcriptional alterations observed in our mouse models 
could find correlation with human tumors counterpart. 
As gene expression datasets containing both NE and 
adenocarcinoma human PCa are not publicly available 
we used GSEA to test whether genes previously identified 
as up- or down- regulated in human prostate NE tumors 
versus prostate adenocarcinomas [27] were positively or 
negatively enriched in mouse NE lesions. Results showed 
that genes over-expressed in NE human tumors were also 
positively enriched in both OPT-tm and Early-NE samples 
(Figure 6C, left, and Figure 6E, left, respectively). The 
core enrichment genes, accounting for the gene set’s 
enrichment, were related to cancer, neuronal development, 
cell growth and cell cycle progression (Figure 6D and 6F, 
and Table S4 and S5), confirming the results obtained 
with the murine NE signatures. Conversely, genes down-
regulated in NE patients were significantly negatively 
enriched in both OPT-tm and Early-NE samples while 
up-regulated in T30 (late adenocarcinoma) and Early-
ADC samples (Figure 6C, right, and Figure 6E, right, 
respectively). Taken together these results showed 
that gene expression profiles of tumors arising in 
OPN−/−TRAMP mice were similar to those of human NE 
prostatic cancers.
DISCUSSION
ECM confers proper architecture and function 
to tissues. It regulates connections and communication 
between cells and is responsible for the continued tissue 
remodeling in development or healing. Of great interest 
is the role of ECM in cancer, representing a tissue that 
does not heal [28], especially in premalignant to malignant 
transition [29].
OPN is an ECM non-structural protein, member 
of the SIBLINGs, endowed with pro-migratory and pro-
angiogenic properties in transformed tissues [30] and 
considered a potential tumor marker [31]. In PCa its 
expression in primary tumors [4] and bone metastases [32] 
correlates with poor prognosis and its targeting has been 
considered a therapeutic option [33].
Despite the numerous studies, none has investigated 
the role of OPN at onset of PCa. The present work is 
the first to study the effect of OPN genetic deficiency 
in TRAMP, a mouse model mimicking human PCa. 
Considering its high expression in advanced human PCa 
we would have expected that OPN knockout in TRAMP 
mice would have delayed tumor onset or reduced tumor 
size. To our surprise, OPN−/−TRAMP mice displayed early 
onset and accelerated tumor development in comparison 
to TRAMP mice. These tumors developed as spherical 
masses, macroscopically detectable at 18 wks of age by 
echographic examination. Histopathology classified these 
tumors as undifferentiated and immunohistochemistry 
indicated the loss of AR, the retention of Tag and the 
gaining of synaptophysin. The same characteristics have 
also been described for NE tumors that seldom develop 
spontaneously in TRAMP mice unless stimulated by 
castration [12, 18]. Castration in TRAMP mice has 
different outcomes depending on the age of mice at 
surgery. Before sexual maturation it causes prostate 
involution and prevents neoplastic transformation [13] 
whereas at late stages it promotes the development 
of androgen independent NE tumors; which express 
high levels of Tag [13, 16, 34]. In OPN−/−TRAMP mice 
castration at either 6 or 12 weeks had no effect on NE 
tumor development, which still occurred at high rate in an 
hormone independent way.
We also found that proliferating Ki67 positive 
cells in prostates of OPN−/−TRAMP mice express 
cytoplasmic p63, thus confirming that the basal prostate 
compartment is transforming in OPN−/−TRAMP mice. 
This is in line with the hypothesis that NE tumors arise 
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Figure 6: Early NE signature from OPN-/-TRAMP mice correlates with human NE tumors. A. Hierarchical clustering of 
early samples obtained from mice free of detectable prostatic lesions (OPT−/−TRAMP 18 wks: light grey; OPN−/−TRAMP 15 wks: dark 
grey and TRAMP 18 wks: black). Refer to Suppl. Table 1 and Suppl. Figure3 for detailed description of samples analyzed and flow chart of 
comparisons. B. Enrichment map showing gene sets significantly enriched in Early-NE compared to Early-ADC according to GSEA. Nodes 
represent gene sets. Node size is proportional to the number of genes in the gene set. Edges connect overlapping gene sets. Edge thickness 
indicates the size of the overlap. Red indicates up-regulation, blue indicates down-regulation. C. GSEA plot showing enrichment of genes 
up-regulated or down-regulated in human NE tumors towards genes over-expressed (left) or down-regulated (right) in OPT-tm compared 
to T30 mice. D. Canonical pathways, identified by functional analysis with IPA of the core set of genes from human NE samples leading 
the enrichment in NE OPT-tm samples. E. GSEA plot showing enrichment of genes up-regulated or down-regulated in human NE tumors 
towards genes over-expressed (left) or down-regulated (right) in Early-NE compared to Early-ADC samples. F. Canonical pathways, 
identified by functional analysis with IPA of the core set of genes from human NE samples leading the enrichment in Early-NE samples.
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from basal stem-like cells in the TRAMP model [12]. The 
cytoplasmic staining of p63 (Figure 4D) is in agreement 
with human PCa, carrying a translocation of p63 from the 
nucleus to the cytoplasm, an event that has been correlated 
with increased cell proliferation and dismal prognosis [21].
Clustering analysis performed on gene lists 
originated by prostate samples from OPN−/− TRAMP of 
18 wks with US detectable NE tumors and by samples 
from 30 wks TRAMP with adenocarcinoma, proved 
the distinct nature of tumors developing early in mice 
deficient for OPN.
In silico analysis showed that genes promoting 
cell cycle were most up-regulated in OPN−/−TRAMP 
than TRAMP tumors. Among them CyclinE2 and E2f2 
are inducible by estrogens [35], indicating their possible 
involvement in the development of androgen independent 
NE tumor [36]. CyclinD1, which promotes cell cycle 
progression in TRAMP adenocarcinomas [37–39], was 
down-regulated in NE tumors from OPN−/−TRAMP mice. 
These data are in line with the observation that up to 90% 
of human NE xenografts show loss of Cyclin D1 [40]. 
The similarity between murine and human NE tumors was 
corroborated by the concordant up-regulation of DDC, a 
biomarker for human NE PCa [41, 42].
The key genes down-regulated in our signature 
belong to the TGFβ pathway and encode for cytoskeletal 
proteins. TGFβ mediates the activity of OPN in 
maintaining hematopoietic stem cells quiescence in the 
mesenchymal BM niche [43]. Not surprisingly, it might 
also maintain dormant the prostatic stem cell compartment 
[26]. The lack of OPN in the prostate stem cell niche may 
inactivate the TGFβ pathway and therefore favor the 
escape from its anti-proliferative control, towards NE 
tumors development.
In keratinocytes Filamin A (FLNA), a cytoskeletal 
SMAD-binding protein, binds SMAD2 for effective 
TFGβ receptor signaling; accordingly, FLNA-deficient 
melanoma cells have impaired TGFβ signaling [25]. In 
OPN−/−TRAMP NE tumors, FLNA was down-regulated 
at gene and protein levels. SMAD3 gene and protein 
were also down-regulated although the residual protein 
was still phosphorylated. SMAD3 is a key intermediated 
in the TGFβ pathway [44] and its depletion cannot be 
overcome by SMAD2 in sustaining TGFβ–mediated cell 
cycle arrest and growth inhibition [45]. Accordingly, a 
reduced expression of SMAD3 diminishes the tumor-
suppressor function of the TGFβ pathway in a model of 
acute T-cell lymphoblastic leukemia [46]. Overall, our 
data support the conclusion that deregulation of TGFβ 
signaling is responsible for increased tumor proliferation 
and aggressiveness in the OPN−/− TRAMP model.
Nested class comparison between Early-NE vs 
Early-ADC tissues identified 184 genes that were all up-
regulated in prostates from OPN-/-TRAMP at the onset of 
the still undetectable NE tumors, and that might contain 
possible biomarkers for early diagnosis.
The validation of OPN−/−TRAMP as a reliable model 
for human NE prostate cancer came from the GSEA 
analysis on Beltran dataset of PCa patients [27]. Indeed, 
genes that are up-regulated in human NE prostate cancers 
were also enriched in our data set from OPN−/−TRAMP 
mice. Common were the genes belonging to canonical 
pathway related to cancer, neuronal development, cell 
growth and cell cycle progression.
Modification of the genetic background has been 
found to change the frequency of NE tumors in TRAMP 
mice [47], suggesting that polymorphic germline modifier 
genes may favor NE tumors in this model. Here, using 
the same C57BL/6 genetic background, we confined to 
OPN the genetic difference, underscoring a role of OPN 
in controlling prostate NE tumor outcome. Although this 
study is the first to demonstrate the role of OPN in prostate 
tumorigenesis, another SIBLINGs member, namely 
SPARC, has been shown to favor the occurrence of more 
aggressive cancers, of undefined histotype in TRAMP 
mice, if deleted [48]. Altogether these data support 
the idea that under the same oncogenic driver (SV40 
large T antigen), the ECM composition can influence 
the phenotype and the aggressiveness of the upcoming 
tumor. Conversely, in advanced PCa patients both OPN 
and SPARC overexpression are associated with poor 
prognosis and metastatic phenotype [4, 32, 49], implying 
that the same ECM proteins can exert different functions 
at different tumor stages.
MATERIALS AND METHODS
Mice
TRAMP mice (C57BL/6-tgN (TRAMP)8247Ng) 
were kindly provided by Dr. Vincenzo Bronte (IRCCS 
Istituto Oncologico Veneto, Padova, Italy), under 
agreement with Dr. Norman Michael Greenberg 
(Fred Hutchinson Cancer Research Center, Seattle, 
USA). TRAMP mice were maintained heterozygous 
(TRAMP+/−) and screened according to [6]. OPN 
knockout mutant B6.129S6(Cg)-Spp1tm1Blh/J (OPN−/−) 
mice were purchased from Jackson Laboratories 
and intercrossed to TRAMP mice, in order to obtain 
congenic B6.tgN (TRAMP)8247Ng Spp1<tm1Blh>/J 
(OPN−/−TRAMP). Female mice heterozygous for Tag 
(TRAMP+/−) and OPN−/− were bred with male OPN−/− 
mice to obtain experimental OPN−/−TRAMP+/− mice, 
which were genotyped for Tag expression [6]. Mice 
were maintained under pathogen-free conditions at the 
animal facility of Fondazione IRCCS Istituto Nazionale 
dei Tumori. Animal experiments were authorized by 
the Institute Ethical Committee and performed in 
accordance to institutional guidelines and national 
law (D.lgs 26/2014). Prostate tumor growth was 
echo-graphically monitored using a Vevo 770 micro-
ultrasound imaging system (Visualsonics Inc., Toronto, 
Oncotarget3916www.impactjournals.com/oncotarget
Canada) as described [50]. Castration was performed 
after anesthesia (100 mg/kg Ketamine, 16 mg/kg 
Xylazine) as described [51].
Histology, immunohistochemistry
Prostates were fixed in formalin and embedded 
in paraffin. 5 μM sections were stained with Mayer-
Hematoxylin and Eosin (H&E). Alternatively, 
after re-hydratation and antigen retrieval, 
immunohistochemistry was performed using the 
streptavidin-biotin-peroxidase complex method, and 
3,3′-Diaminobenzidine tetrahydrochloride as chromogenic 
substrate. Primary antibodies were: Ki67 (TEC-3, Dako, 
Glostrup Denmark), N-cadherin (Abcam, Cambridge, 
MA, USA), Laminin (Biodesign, Memphis, TN, USA), 
Androgen Receptor (Merck Millipore, Milano, Italy) 
Synaptophysin (Abcam,), SV40 Tag (clone pAb101, BD 
Biosciences, Buccinasco Italy), OPN (AbCam). Slides 
were analyzed under a Leica DM2000 optical microscope 
equipped with a Leica DFC320 digital camera (Leica 
Microsystems, Milan, Italy).
Immunofluorescence
Sections were incubated with primary antibody anti 
Ki67 o/n at 4°C, then washed in PBS and incubated for 1h 
with an Alexa-488 anti-rabbit antibody. Slides were then 
incubated with anti CK8 or anti p63 antibodies (Abcam) 
for 1h, washed and further incubated with Alexa-568 
anti-mouse antibody. Sections were counter stained with 
DAPI and analyzed with a Microradiance 2000 (Bio-
Rad Laboratories, Segrate, Italy) confocal microscope 
equipped with Ar (488 nm), HeNe (543 nm) and red laser 
diode (638 nm) lasers. Confocal images (512 × 512 pixels) 
were obtained using a x200, 0.5 NA Plan Fluor DIC or 
x600 1.4 NA oil immersion lens and analyzed using 
ImagePro 7.0.1 software.
RT-qPCR
Prostates were lysed with TRIzol (Invitrogen, 
Life Technologies, Monza, Italy) and RNA was 
purified by phenol/chloroform extraction followed 
by loading onto RNeasy MINI kit (Qiagen, Milan, 
Italy). On-column DNAse treatment was performed. 
RNA purity and yield was assessed using NanoDrop 
ND-100 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE).
RNA was Reverse Transcribed using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). 
RT-qPCR reaction was prepared using TaqMan (R) 
Fast Universal PCR Master Mix and run on a 7900 HT 
Fast Real-time PCR System (Applied Biosystems, Life 
Technologies, Monza, Italy) as described previously [52]. 
The following TaqMan(R) probes were used: Gapdh 
(Mm99999915_g1), Ccne2 (Mm00438077_m1), Ccnd1 
(Mm00432359_m1), E2f2 (Mm00624964_m1), Ddc 
(Mm00516688_m1), Syp (Mm00436850_m1). Expression 
values were normalized to internal control (Gapdh) and to 
control sample (TRAMP prostate) calculating the ΔΔCT.
Western blot
Ten sections of 10 mm from frozen samples of 
TRAMP or OPN−/−TRAMP tumors were lysed, run on a 
4-12% Bis-Tris Gel (Invitrogen) and transferred on a NC 
membrane (Amersham, GE Healthcare, Milano, Italy). 
Primary antibodies against Smad3, Smad2, phospho 
Smad2, phospho Smad3, Filamin, DDC and Syp were 
from Cell Signaling Technology, against β-actin from 
SIGMA Aldrich. Secondary HRP antibodies were goat 
anti-rabbit and rabbit anti-goat (Invitrogen). Densitometric 
analysis was performed using the ImageJ 1.48v software 
(http://imagej.nih.gov/ij).
Gene expression profiling
We collected prostates from 18 wks old TRAMP mice 
(T18, n = 4), with null or minimal disease, from 30 wks 
old TRAMP mice (T30, n = 4) in which adenocarcinoma 
was palpable and detectable by US, from OPN−/−TRAMP 
mice of 15 or 18 wks of age (OPT15, n = 5 and OPT18, n 
= 9, respectively) without any detectable lesion and from 
18 wks old OPN−/−TRAMP mice with detectable NE tumor 
mass (OPT18tm, n = 3). A detailed description of samples 
used for microarray comparison is in Suppl. Table 1, and a 
detailed flow chart depicting how samples were compared is 
in Suppl. Figure 3
RNA was isolated using the guanidinium 
thiocyanate/cesium chloride gradient method [53]. RNA 
concentrations were measured with the NanoDrop ND-100 
Spectrophotometer (NanoDrop Technologies) while RNA 
quality was assessed with the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, CA, USA) using the 
RNA 6000 Nano kit (Agilent Technologies). The mean 
RIN value was 8.028 (SD = 0.65). RNA samples were 
processed for microarray hybridization by the Functional 
Genomics core facility at Fondazione IRCCS Istituto 
Nazionale dei Tumori, Milan. Briefly, 800 ng of total RNA 
was reverse transcribed, labeled with biotin and amplified 
overnight (14 hours) using the Illumina RNA TotalPrep 
Amplification kit (Ambion, Life Technologies, Grand 
Island, NY, USA) according to manufacturer’s protocol. 
One μg of the biotinylated cRNA sample was mixed with 
the Hyb E1 hybridizatioin buffer containing 37.5% (w/w) 
formamide and then hybridized to array MouseRef-8 
v2.0 Expression BeadChip (Illumina, Inc., San Diego, 
CA, USA) at 58°C overnight (18 hours). Array chips 
were washed with manufacturer’s E1BC solution, stained 
with 1 μg/ml Cy3-streptavidine (Amersham Biosciences; 




Raw expression data were collected from scanned 
images using Illumina BeadStudio v3.3.8 and processed 
using the lumi package from Bioconductor [54]. Quality 
control was performed on raw and processed data by 
evaluation of array intensity distributions, distances 
between arrays, and by principal component analysis 
for the identification of possible outliers. All samples 
passed quality-control procedures. Raw data were log2-
transformed, normalized with robust spline normalization 
and filtered, keeping only the probes with a detection 
p-value < 0.01 in at least one sample. Among probes 
mapping on the same gene the most detected one was 
chosen. All array data have been deposited in NCBI’s 
Gene Expression Omnibus and are accessible through 
GEO Series accession number GSE69903.
Microarray data analysis
Differentially expressed genes between classes 
were identified using the limma package [55]. P-values 
were corrected for multiple testing using the Benjamini-
Hochberg false discovery rate method. An FDR < 0.05 
and an absolute fold change ≥ 2 were used as criteria for 
selection of differentially expressed genes. Agglomerative 
hierarchical clustering was performed using average 
linkage and 1-Pearson’s correlation coefficient as distance 
measure. Gene Set Enrichment Analysis (GSEA [56]) 
was applied to identify biological processes enriched in 
the different groups. Gene sets were retrieved from the c2 
canonical pathways and c5 biological process collections 
from the MSigDB database (http://www.broadinstitute.
org/gsea/msigdb/index.jsp). Significantly enriched gene 
sets (p < 0.001 and FDR< 0.05) were visualized using 
Cytoscape v2.8.3 and the Enrichment Map plugin [57]. 
Functional analyses of gene lists were generated through 
the use of IPA(QIAGEN, www.qiagen.com/ingenuity).
Statistical analysis
We used GraphPad Prism software (GraphPad 
Software, La Jolla, CA, USA). Student’s t-test was used 
for comparison of quantitative variables. Association 
between categorical variables was carried out using 
Fisher’s exact test. Log-Rank test was applied for survival 
curves. All statistical tests were two-sided and a p-value 
<0.05 was considered significant.
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